by Wiley Credit: Pixabay/CC0 Public DomainResearch in animals has shown that the diabetes drug dulaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist may reduce symptoms of depression. A new study published in Brain and Behavior reveals the mechanisms that are likely involved. By conducting a range of tests in mice treated with and without dulaglutide,...
by Karolinska Institutet Credit: Pixabay/CC0 Public DomainOzempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut. GLP1 agonists like Ozempic reduce blood sugar levels...
by British Medical Journal Credit: Pixabay/CC0 Public Domain The diabetes drug dulaglutide (Trulicity) may significantly lower a woman’s risk of substantial weight gain after she has given up smoking, finds a secondary analysis of clinical trial data, published in the open access journal BMJ Nutrition Prevention & Health. Women seem to be five times as likely...
Peer-Reviewed Publication CASE WESTERN RESERVE UNIVERSITY NATHAN BERGER CREDIT: CASE WESTERN RESERVE UNIVERSITY CLEVELAND—A groundbreaking study by researchers at Case Western Reserve University suggests a class of medications used to treat type 2 diabetes may also reduce the risk of colorectal cancer (CRC). The findings, published today (Dec. 7) in the journal JAMA Oncology, support...
by Justin Jackson, Medical Xpress Discovery and inhibition of a gut microbial–host isozyme to regulate host metabolism. Differences in the gut microbiota may explain why some individuals respond to antidiabetic DPP4 inhibitors but others do not. An activity-based enzyme activity screening system identified gut microbial DPP4 isozymes that can decrease active GLP-1 but cannot be...
Megan Brooks February 16, 2023 Treatment with the thiazolidinedione pioglitazone may offer the greatest protection against dementia for older adults with newly diagnosed type 2 diabetes mellitus (T2DM) who have a history of stroke or ischemic heart disease, new research suggests. Overall, in a large cohort study from Korea, patients who took pioglitazone were 16% less likely to develop dementia over an average of...
Carolyn Crist March 09, 2023 Metformin appears to play a role in preventing long COVID when taken early during a COVID-19 infection, according to a new preprint study from The Lancet. The preprint hasn’t yet been peer-reviewed or published in a journal. In particular, metformin led to a 42% drop in long COVID among people who had a mild to...
Megan Brooks February 16, 2023 Treatment with the thiazolidinedione pioglitazone may offer the greatest protection against dementia for older adults with newly diagnosed type 2 diabetes mellitus (T2DM) who have a history of stroke or ischemic heart disease, new research suggests. Overall, in a large cohort study from Korea, patients who took pioglitazone were 16% less likely to develop dementia over an...
by Monash University Incidence of major adverse cardiovascular events (MACE) in men and women dispensed either a sodium glucose co-transporter 2 inhibitor (SGLT2i) or glucagon-like peptide receptor 1 agonist (GLP-1RA) 60-days after their index discharge date. Follow up of people is until 30th June 2018. Symbols on curves indicate competing risk events (i.e. non-MACE related...
by Lisa M. Krieger, The Mercury News Credit: CC0 Public Domain Is an ancient compound the new “wonder drug”? Metformin, a common medication to control diabetes, has become the controversial darling of tech’s health-conscious digerati who are enticed by preliminary research suggesting it might help promote longevity, reduce dementia and prevent a whole host of other conditions—including,...
